Pipeline

With currently more than 80 distinct drugs in research and development, MorphoSys has one of the broadest antibody pipelines in the biotechnology industry. 20 different therapeutic antibodies are already being evaluated in clinical trials and tested as options for treatment of severe and in many cases life-threatening diseases. The Company’s product pipeline comprises both partnered and proprietary antibody therapeutic development programs, as shown below:

Pipeline

Discovery Preclinic Phase 1 Phase 2 Phase 3 Market
Bimagrumab, Novartis

Bimagrumab (BYM338), Novartis

  • A fully human HuCAL-based antibody to treat musculoskeletal diseases
  • Target: ActRIIB

Additional information:

Gantenerumab, Roche

Gantenerumab, Roche

  • A fully human HuCAL-based antibody to treat Alzheimer‘s disease
  • Target: Amyloid-beta

Additional Information:

MOR103, GSK

MOR103, MorphoSys & GlaxoSmithKline

  • A fully human HuCAL antibody for the treatment of inflammatory diseases like rheumatoid arthritis or multiple sclerosis
  • Target: Granulocyte macrophage colony-stimulating factor (GM-CSF)

Additional information:

 

MOR103, MorphoSys

  • A fully human HuCAL antibody for the treatment of inflammatory diseases like rheumatoid arthritis or multiple sclerosis
  • Target: Granulocyte macrophage colony-stimulating factor (GM-CSF)

Additional information:

MOR208

MOR208, MorphoSys

  • A Fc-optimized antibody to treat B-cell malignancies (incl. CLL/SLL, B-ALL & NHL)
  • Target: CD19

Additional Information:

Guselkumab, Janssen

Guselkumab (CNTO 1959), Janssen

  • A fully human HuCAL-based antibody to treat Psoriasis and Rheumatoid Arthritis
  • Target: IL23p19

Additional Information:

 

Guselkumab (CNTO 1959), Janssen

  • A fully human HuCAL-based antibody to treat Psoriasis and Rheumatoid Arthritis
  • Target: IL23p19

Additional Information:

BHQ880, Novartis

BHQ880, Novartis

  • A fully human HuCAL-based antibody to treat osteolytic bone disease in multiple myeloma patients
  • Target: Dickkopf-1 (DKK-1)

Additional Information:

Novartis
LFG316, Novartis

LFG316, Novartis

  • A fully human HuCAL-based antibody developed in Ophthalmology 
  • Target: C5

Additional Information:

OMP-59R5, OncoMed

OMP-59R5, OncoMed

 

  • A fully human HuCAL-based antibody to treat pancreatic cancer
  • Target: Notch receptor (Notch 2)

Additional Information:

CNTO 3157, Janssen

CNTO 3157, Janssen

  • A fully human HuCAL-based antibody to treat Asthma

Additional Information:

 

CNTO 6785, Janssen

CNTO 6785, Janssen

  • A fully human HuCAL-based antibody to treat Rheumatoid Arthritis

Additional Information:

VAY736, Novartis

VAY736, Novartis

  • A fully human HuCAL-based antibody to treat inflammatory diseases & cancer
  • Target: BAFF-R

Additional information:

MOR202, Celgene

MOR202, MorphoSys & Celgene

  • A fully human HuCAL-based antibody to treat Multiple Myeloma
  • Target: CD38

Additional Information:

BAY 94-9343, Bayer HealthCare

BAY 94-9343, Bayer HealthCare

  • A fully human HuCAL-based antibody drug conjugate to treat mesotheliomas and ovarian and pancreatic carcinomas
  • Target: Mesothelin

Additional Information:

BI 836845, Boehringer Ingelheim

BI 836845, Boehringer Ingelheim

  • A fully human HuCAL-based antibody to treat cancer
  • Target: IGF-1

Additional Information:

LJM716, Novartis

LJM716, Novartis

  • A fully human HuCAL-based antibody to treat cancer
  • Target: HER3

Additional information:

Vantictumab, OncoMed

Vantictumab (OMP-18R5), OncoMed

  • A fully human HuCAL-based antibody to treat solid tumors
  • Target: Wnt signaling pathway (Fzd 7)

Additional information:

PF-05082566, Pfizer

PF-05082566, Pfizer

  • A fully human HuCAL-based antibody to treat cancer
  • Target: 4-1BB (CD137)

Additional Information:

Novartis
Novartis
21 Partnered Programs
3 Proprietary Programs
37 Partnered Programs

Print Pipeline

Partnered Programs

MOR Programs

5-Year-Overview

Clinical Pipeline

 

Clinical Trials

MorphoSys is currently involved in several active clinical trials.